Treatment with carfilzomib. Should these patients be admitted in the Intensive Care Unit?
Med Intensiva (Engl Ed). 2018 Jan-Feb;42(1):60-62.
doi: 10.1016/j.medin.2017.02.004.
Epub 2017 Mar 16.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Medicina Intensiva, Hospital Universitario Central de Asturias, Oviedo, España. Electronic address: rakel_20r@hotmail.com.
- 2 Servicio de Medicina Intensiva, Hospital Universitario Central de Asturias, Oviedo, España.
No abstract available
Publication types
-
Case Reports
-
Letter
-
Review
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Combined Modality Therapy
-
Critical Care*
-
Dexamethasone / administration & dosage
-
Fatal Outcome
-
Heart / drug effects
-
Heart Arrest / chemically induced*
-
Heart Arrest / therapy
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Lenalidomide / administration & dosage
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy
-
Multiple Myeloma / therapy
-
Oligopeptides / administration & dosage
-
Oligopeptides / adverse effects*
-
Protease Inhibitors / administration & dosage
-
Protease Inhibitors / adverse effects*
-
Pulmonary Edema / chemically induced*
-
Pulmonary Edema / therapy
-
Recurrence
-
Salvage Therapy
-
Transplantation, Autologous
Substances
-
Oligopeptides
-
Protease Inhibitors
-
carfilzomib
-
Dexamethasone
-
Lenalidomide